Ariad Pharmaceuticals files $125 million stock, preferreds, debt shelf

By Devika Patel

Knoxville, Tenn., Jan. 11 - Ariad Pharmaceuticals Inc. filed a $125 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, debt securities, warrants, rights, purchase contracts and units.

The securities may be structured as convertibles.

The proceeds will be used for operations, working capital and general corporate purposes.

Ariad is a pharmaceutical company based in Cambridge, Mass., that develops medicines to treat cancer by regulating cell signaling with small molecules.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.